Liquidia Technologies Inc

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The company was founded on June 28, 2020 and is headquartered in Morrisville, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Liquidia Technologies reports robust Q4 earnings, eyes YUTREPIA's market potential

Liquidia Technologies Inc (LQDA) showcased strong financial performance and promising prospects for its flagship product, YUTREPIA, in the pharmaceutical market. While facing challenges in legal proceedings and market competition, the company's focus on innovation, clinical trials, and strategic positioning bodes well for future growth and success.

Liquidia Technologies navigates legal hurdles to capitalize on YUTREPIA

Liquidia Technologies faces financial challenges with a net loss in Q1 2023 but holds a strong cash position. The success of YUTREPIA hinges on navigating legal hurdles and effectively differentiating itself in the market.

Liquidia Technologies reports solid Q2 results amidst legal victories

Liquidia Technologies Inc's Q2 2023 Earnings Call highlighted strong financials, legal victories, and strategic focus on R&D. While facing legal challenges and balancing expenses, the company remains confident in its progress. Opportunities in FDA approvals, clinical development, and strategic partnerships present avenues for growth.

Liquidia Technologies Inc (LQDA) reports strong progress and prepares for market expansion

Liquidia Technologies Inc (LQDA) made significant strides in developing inhaled treprostinil products, showcasing promising results and clear benefits.
While facing regulatory and market challenges, the company's strong commercial preparations and financial prudence position it well for future growth.
Opportunities in market expansion, successful product launches, and program development offer avenues for revenue growth and industry leadership.

Liquidia Technologies eyes FDA approval for YUTREPIA, targeting $3B market

Liquidia Technologies is poised for growth with a strong financial position and strategic focus on YUTREPIA to lead the treprostinil market.
While facing regulatory and operational challenges, the company's emphasis on addressing patient dosing effectively presents opportunities for market leadership.
The potential FDA approval of YUTREPIA post-March 31 opens doors to a $3 billion market opportunity, positioning the company for significant growth.

Liquidia Technologies reports strong Q1 performance and eyes market expansion

Liquidia Technologies Inc's Q1 2024 earnings call highlighted strong financial performance, market potential in inhaled treprostinil products, legal progress, and a focus on innovation. The company is well-positioned for commercial launch post-approval and aims to address the growing market demand for improved treatment options.

Liquidia Technologies reports Q2 results, eyes pulmonary hypertension market

Liquidia Technologies Inc reported mixed financial results for Q2 2024, with revenue of $3.7 million and a net loss.
The company's focus on YUTREPIA and L606 formulations presents promising opportunities in the pulmonary hypertension space.
Analyst inquiries highlighted key areas of interest, including product benefits, trial data, regulatory matters, and financial outlook.
With a strong cash position and ongoing FDA engagement, Liquidia is poised for potential growth and advancement in its pipeline.

Liquidia Technologies reports strong Q3 performance amidst regulatory challenges

Liquidia Technologies Inc's Q3 2024 Earnings Call highlighted strong financial performance, progress towards YUTREPIA approval, and strategic plans for product launch. Legal challenges and regulatory hurdles pose significant challenges, while opportunities for growth exist in product development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Liquidia Corp. operates as a holding company which through its subsidiary engages in developing and commercializing biopharmaceutical products. It engages in novel products development used in PRINT technology to transform the lives of patients. The company was founded on June 28, 2020, and is headquartered in Morrisville, NC.

Arlo Technologies Inc

Ituran Location & Control

Rada Electronic

Sierra Wireless

Veritone

XBiotech

When Wall Street ignores micro-cap stocks, it creates deep value opportunities, if a company is able to turn things around against fortune.

7 Micro-Cap Stocks You May Want to Take a Chance On

Liquidia Technologies Inc. (NASDAQ: LQDA) has seen its share of news after an acquisition and a recent stock sale.

Pulmonary Arterial Hypertension Could Help Liquidia Technologies Stock Rise Over 300%

RESEARCH TRIANGLE PARK, N.C., July  02, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced the closing of its previously announced underwritten public offering of 9,375,000 shares of its common stock at a public offering price of $8.00, for total gross proceeds of $75 million, before deducting underwriting discounts and commissions and expenses payable by Liquidia. All of the shares in the offering were sold by Liquidia. In addition, Liquidia has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less the underwriting discount and commissions.

Liquidia Announces Closing of Public Offering of Common Stock

BioCryst Pharmaceuticals

Fluent Inc

GrubHub

MannKind

Today has brought good news. Consumer confidence is better than expected and unemployment has decreased.

Top Stocks To Short As Consumer Confidence Exceeds Expectations

RESEARCH TRIANGLE PARK, N.C., June  29, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announced it has entered into a definitive agreement to acquire RareGen, LLC, a portfolio company of PBM Capital, through an all-stock merger. Liquidia and RareGen will consolidate under a new holding company, to be named Liquidia Corporation, which is expected to trade on the Nasdaq Capital Market under the ticker symbol “LQDA,” as the successor to Liquidia Technologies.  RareGen provides strategy, investment, and commercialization for rare disease pharmaceutical products. RareGen has a small, targeted sales force focused on PAH.

Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH

Aeglea BioTherapeutics

Dynavax Technologies

PhaseBio Pharmaceuticals Inc

Seelos Therapeutics

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shorts today.

Top Stocks To Short As Markets Rebound Ignores Disappointing Monday

Blink Charging

Navidea Biopharma

Savara

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts for you to hedge out or bet with your portfolio today.

Top Stocks To Short With VIX Rallying

RESEARCH TRIANGLE PARK, N.C., June  05, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that United Therapeutics Corporation (UTC) filed a patent infringement action under the Hatch-Waxman Act against the Company in the U.S. District Court for the District of Delaware asserting infringement of U.S. Patent Nos. 9,604,901 (‘901) and 9,593,066 (‘066) relating to UTC’s Tyvaso, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension (PAH).

Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of Tyvaso Patents

Liquidia Technologies (LQDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Liquidia Technologies (LQDA) Stock Might be a Great Pick?

RESEARCH TRIANGLE PARK, N.C., May  18, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced the appointment of Tushar Shah, M.D., to the newly created position of Chief Medical Officer. In this role, Dr. Shah will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia. Dr. Shah has 27 years of pharmaceutical research and development experience, successfully moving more than 20 products from discovery to commercialization.

Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer

Liquidia Technologies' (LQDA) CEO Neal Fowler on Q1 2020 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., April  30, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that it has released final safety and tolerability results from the two-month endpoint of the pivotal phase 3 INSPIRE trial that evaluated LIQ861 in patients with pulmonary arterial hypertension (PAH). Details from this late-breaking abstract were provided as an ePresentation on ISHLTv, an online platform designed as an alternative to the face-to-face scientific exchange originally scheduled at the International Society for Heart & Lung Transplantation (ISHLT) Annual Meeting.

Liquidia Releases Final LIQ861 Results from Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension

RESEARCH TRIANGLE PARK, N.C., April  08, 2020  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the Company’s New Drug Application (NDA) seeking marketing approval for LIQ861 for the treatment of pulmonary arterial hypertension (PAH). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a goal date of November 24, 2020. 

Liquidia Announces FDA Acceptance of New Drug Application for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension

Liquidia Technologies, Inc. (LQDA) CEO Neal Fowler on Q4 2019 Results - Earnings Call Transcript

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -38.46% and -100.00%, respectively, for the quarter ended December 2019.

Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Misses Revenue Estimates

Liquidia Technologies, Inc. (LQDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Liquidia Technologies, Inc. (LQDA) Report Negative Earnings Next Week?

As of late, it has definitely been a great time to be an investor in Liquidia.

Will Liquidia Continue to Surge Higher?

Shares of Liquidia Technologies Inc. LQDA, +49.01% , a Durham, N.C.-based biotech, soared more than 70% Thursday before paring their gains, after Wedbush reiterated an outperform rating on the stock and said a $22.4 million fundraising will give the company the runway to keep going through the fourth quarter of 2020.

Liquidia Technologies stock soars after Wedbush says private placement gives company runway through Q4 2020

RESEARCH TRIANGLE PARK, N.C., Dec.  24, 2019  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT® technology, today announced that it has entered into a common stock purchase agreement (the “Purchase Agreement”) with certain institutional accredited investors for the private placement of 7,164,534 shares of common stock at a purchase price of $3.13 per share, yielding expected gross proceeds of approximately $22.4 million. The private placement is expected to close on or about December 27, 2019, subject to the satisfaction of customary closing conditions. Jefferies acted as the sole placement agent to Liquidia in connection with the private placement.  Net proceeds from this private placement are expected to be used to complete ongoing development of LIQ861 and LIQ865 and for general corporate purposes. The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Liquidia has agreed to file a registration statement with the U.S. Securities and Exchange Commission registering the resale of the shares of common stock to be issued and sold in the private placement no later than the 60th day after its entry into the Purchase Agreement. Any offering of the securities under the resale registration statement will only be made by means of a prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.  About Liquidia  Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary PRINT technology to transform the lives of patients. Currently, Liquidia is focused on the development of two product candidates using its PRINT particle engineering platform: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Having been evaluated in a phase 3 clinical trial (INSPIRE), LIQ861 is designed to improve the therapeutic profile of treprostinil by enhancing deep-lung delivery and achieving higher dose levels than current inhaled therapies by using a convenient, palm-sized, disposable dry powder inhaler. LIQ865, for which Liquidia has completed two phase 1 clinical trials, is designed to deliver sustained-release particles of bupivacaine, a non-opioid anesthetic, to treat local post-operative pain for three to five days through a single administration.  Cautionary Note Regarding Forward-Looking Statements  This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, including the potential licensing of LIQ861, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding the anticipated closing of the private placement, the use of proceeds from the private placement, the filing of a registration statement to register the resale of the shares to be issued and sold in the private placement, clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related timelines, including the filing of a New Drug Application (NDA) for LIQ861 and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs, including but not limited to whether the conditions for the closing of the private placement will be satisfied. These forward-looking statements are subject to a number of risks discussed in our filings with the Securities and Exchange Commission, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.  Contact Information  Investors: Jason AdairVice President, Corporate Development and Strategy919.328.4400 jason.adair@liquidia.com   Media:    Christy Curran Sam Brown Inc.  615.414.8668  media@liquidia.com  

Liquidia Technologies Announces $22.4 Million Private Placement

Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q3 2019 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Nov.  01, 2019  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Katie Rielly-Gauvin, Vice President of Global Commercial Development at AbbVie, to the Company’s Board of Directors (the “Board”) as a Class II director with a term expiring at the 2020  annual meeting of stockholders and to the Company’s Research and Development Committee and Nominating & Governance Committee. 

Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors

Liquidia Technologies, Inc. (LQDA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

RESEARCH TRIANGLE PARK, N.C., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the Cantor 2019 Global Healthcare Conference on Wednesday, October 2, 2019 at 5:20 p.m. ET. This event will be held at the Intercontinental Barclay hotel in New York City, NY. 

Liquidia to Present at Cantor 2019 Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Sept.  12, 2019  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, today announced the appointment of Joanna Horobin, M.B., Ch.B., to the Company’s Board of Directors (the “Board”) as a Class I director for a term expiring at the 2022 annual meeting of stockholders and to the Company’s Research and Development Committee. 

Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors

RESEARCH TRIANGLE PARK, N.C., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia” or the “Company”), a late-stage clinical biopharmaceutical company, announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, September 10, 2019, at 1:45 p.m. ET in New York, NY.

News for Liquidia Technologies Inc Stock (LQDA)